{
  "id": "mhgap#risk_safety_c2cf631a",
  "title_en": "General — Risk Safety",
  "title_vi": "General — Nguy cơ An toàn",
  "text_en": "3. Recommendations This guideline includes 48 updated and new evidence- based on new/updated systematic reviews while the based recommendations related to MNS conditions. remaining recommendations were based on existing/ These are based on 30 updated PICO questions previously published systematic reviews. that were used for the previous mhGAP guideline The 48 updated and new recommendations are (2015), and 18 new PICO questions developed for presented in this chapter by module (sections this new edition of the guideline. For one other 3.1–3.11). For each recommendation, the updated research question the evidence was relevant justification, remarks, research gaps and insufficient to support an updated recommendation implementation considerations are also presented. so the pre-existing recommendation continues to be The evidence profiles are available online. endorsed; also for one other new research question there was insufficient evidence to support a new The updated and new recommendations in this recommendation. Fourteen recommendations/ guideline stand alongside 90 pre-existing guideline questions (ALC1, ALC2, ALC3, ALC4, CAMH1, STR1, recommendations which were validated and continue STR2, DRU1, DRU3, DRU4, EPI1, EPI2, OVE1, SUI3) were to be endorsed in their current format (7). Mental Health Gap Action Programme (mhGAP) guideline for mental, neurological and substance use disorders 3.1 Alcohol use disorders (ALC) ALC1. In adults with alcohol dependence post-detoxification, is baclofen effective for relapse prevention and management of alcohol dependence? Recommendation (update): Baclofen should be considered for treatment of adults with alcohol dependence post-detoxification. Strength of recommendation: Conditional Certainty of evidence: Moderate Justification y Post-detoxification refers to completion of the y A systematic review was updated: Agabio et al., 2023 management of withdrawal symptoms at least (17 RCTs) (25). three days before starting treatment. Most included studies required participants to abstain from y Compared with placebo, baclofen decreases the alcohol for at least three days (3–28) before risk of relapse into any drinking at end of treatment beginning the pharmacological treatment. (high certainty) and increases the percentage of days abstinent at end of treatment (moderate certainty). y Service providers should include appropriate",
  "gloss_vi": "3. recommendations this guideline includes 48 updated and new evidence- based on new/updated systematic reviews while the based recommendations related to mns conditions.",
  "source": "WHO mhGAP-IG 2023",
  "url": "https://www.who.int/",
  "lang": "en",
  "axes": {
    "type": [
      "clinical"
    ],
    "condition": [
      "General"
    ],
    "clinical_section": [
      "risk_safety",
      "screening_cues",
      "referral",
      "psychoeducation",
      "management"
    ],
    "life_topics": [],
    "advice_section": [],
    "audience": [],
    "risk_band": "low"
  },
  "index_text": "General — Risk Safety General — Nguy cơ An toàn 3. Recommendations This guideline includes 48 updated and new evidence- based on new/updated systematic reviews while the based recommendations related to MNS conditions. remaining recommendations were based on existing/ These are based on 30 updated PICO questions previously published systematic reviews. that were used for the previous mhGAP guideline The 48 updated and new recommendations are (2015), and 18 new PICO questions developed for presented in this chapter by module (sections this new edition of the guideline. For one other 3.1–3.11). For each recommendation, the updated research question the evidence was relevant justification, remarks, research gaps and insufficient to support an updated recommendation implementation considerations are also presented. so the pre-existing recommendation continues to be The evidence profiles are available online. endorsed; also for one other new research question there was insufficient evidence to support a new The updated and new recommendations in this recommendation. Fourteen recommendations/ guideline stand alongside 90 pre-existing guideline questions (ALC1, ALC2, ALC3, ALC4, CAMH1, STR1, recommendations which were validated and continue STR2, DRU1, DRU3, DRU4, EPI1, EPI2, OVE1, SUI3) were to be endorsed in their current format (7). Mental Health Gap Action Programme (mhGAP) guideline for mental, neurological and substance use disorders 3.1 Alcohol use disorders (ALC) ALC1. In adults with alcohol dependence post-detoxification, is baclofen effective for relapse prevention and management of alcohol dependence? Recommendation (update): Baclofen should be considered for treatment of adults with alcohol dependence post-detoxification. Strength of recommendation: Conditional Certainty of evidence: Moderate Justification y Post-detoxification refers to completion of the y A systematic review was updated: Agabio et al., 2023 management of withdrawal symptoms at least (17 RCTs) (25). three days before starting treatment. Most included studies required participants to abstain from y Compared with placebo, baclofen decreases the alcohol for at least three days (3–28) before risk of relapse into any drinking at end of treatment beginning the pharmacological treatment. (high certainty) and increases the percentage of days abstinent at end of treatment (moderate certainty). y Service providers should include appropriate 3. recommendations this guideline includes 48 updated and new evidence- based on new/updated systematic reviews while the based recommendations related to mns conditions."
}